Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced the approval of inducement awards for six new employees. The Compensation Committee of Avadel's Board of Directors granted non-statutory options to purchase 34,200 ordinary shares under the company's 2021 Inducement Plan.
The options have a 10-year term and follow a four-year vesting schedule, with 25% vesting annually, starting from each employee's first anniversary. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato l'approvazione di premi di incentivo per sei nuovi dipendenti. Il Comitato per la Remunerazione del Consiglio di Amministrazione di Avadel ha concesso opzioni non statutarie per l'acquisto di 34.200 azioni ordinarie nell'ambito del Piano di Incentivazione 2021 della società.
Le opzioni hanno una durata di 10 anni e seguono un piano di maturazione quadriennale, con il 25% che matura ogni anno, a partire dal primo anniversario di ciascun dipendente. Questi premi sono stati concessi in conformità alla Regola 5635(c)(4) del Nasdaq come incentivo per l'accettazione dell'impiego.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha anunciado la aprobación de premios de incentivo para seis nuevos empleados. El Comité de Compensación de la Junta Directiva de Avadel otorgó opciones no estatutarias para comprar 34,200 acciones ordinarias bajo el Plan de Incentivos 2021 de la compañía.
Las opciones tienen un plazo de 10 años y siguen un calendario de adquisición de derechos de cuatro años, con un 25% que se adquiere anualmente, comenzando desde el primer aniversario de cada empleado. Estos premios se concedieron de acuerdo con la Regla 5635(c)(4) del Nasdaq como incentivo para la aceptación del empleo.
Avadel Pharmaceuticals (나스닥: AVDL)는 여섯 명의 신입 사원을 위한 인센티브 수여 승인을 발표했습니다. Avadel 이사회 보상위원회는 회사의 2021년 인센티브 계획에 따라 34,200 보통주를 매수할 수 있는 비법정 옵션을 부여했습니다.
이 옵션은 10년 만기이며 4년간의 권리 확정 일정에 따라 매년 25%씩 권리가 확정되며, 각 직원의 첫 번째 기념일부터 시작됩니다. 이 수여는 고용 수락을 위한 유인책으로서 나스닥 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Avadel Pharmaceuticals (Nasdaq : AVDL) a annoncé l'approbation d'attributions incitatives pour six nouveaux employés. Le comité de rémunération du conseil d'administration d'Avadel a accordé des options non statutaires d'achat de 34 200 actions ordinaires dans le cadre du Plan d'Induction 2021 de la société.
Les options ont une durée de 10 ans et suivent un calendrier d'acquisition sur quatre ans, avec 25 % qui s'acquièrent chaque année, à partir du premier anniversaire de chaque employé. Ces attributions ont été accordées conformément à la règle 5635(c)(4) du Nasdaq comme incitation à l'acceptation de l'emploi.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat die Genehmigung von Anreizprämien für sechs neue Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands von Avadel hat nichtstatutarische Optionen zum Kauf von 34.200 Stammaktien im Rahmen des Inducement-Plans 2021 des Unternehmens gewährt.
Die Optionen haben eine Laufzeit von 10 Jahren und folgen einem vierjährigen Vesting-Zeitplan, wobei jährlich 25 % vesten, beginnend mit dem ersten Jahrestag jedes Mitarbeiters. Diese Prämien wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Annahme der Beschäftigung gewährt.
- None.
- None.
DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com
FAQ
What type of stock options did Avadel Pharmaceuticals (AVDL) grant to new employees?
What is the vesting schedule for Avadel's (AVDL) new employee stock options?
How long is the term of the stock options granted by Avadel (AVDL)?
Under which rule were Avadel's (AVDL) inducement awards granted?
